tetano
Editor, Senior Moderator
J Autoimmun. 2020 Apr 17:102468. doi: 10.1016/j.jaut.2020.102468. [Epub ahead of print]
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
Perricone C[SUP]1[/SUP], Triggianese P[SUP]2[/SUP], Bartoloni E[SUP]1[/SUP], Cafaro G[SUP]1[/SUP], Bonifacio AF[SUP]1[/SUP], Bursi R[SUP]1[/SUP], Perricone R[SUP]2[/SUP], Gerli R[SUP]3[/SUP].
Author information
Abstract
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-α has been demonstrated. Moreover, high levels of IL-6 and TNF-α have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
KEYWORDS:
Autoimmunity; Biologics; COVID-19; Coronavirus; DMARDs; IL-6; Immunosuppressant. IL-1; Infection; Rheumatic; SARS-CoV-2; tDMARDs
PMID:32317220DOI:10.1016/j.jaut.2020.102468
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
Perricone C[SUP]1[/SUP], Triggianese P[SUP]2[/SUP], Bartoloni E[SUP]1[/SUP], Cafaro G[SUP]1[/SUP], Bonifacio AF[SUP]1[/SUP], Bursi R[SUP]1[/SUP], Perricone R[SUP]2[/SUP], Gerli R[SUP]3[/SUP].
Author information
Abstract
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-α has been demonstrated. Moreover, high levels of IL-6 and TNF-α have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
KEYWORDS:
Autoimmunity; Biologics; COVID-19; Coronavirus; DMARDs; IL-6; Immunosuppressant. IL-1; Infection; Rheumatic; SARS-CoV-2; tDMARDs
PMID:32317220DOI:10.1016/j.jaut.2020.102468